Avidity Biosciences to Participate in Upcoming Investor Conferences
Avidity Biosciences (NASDAQ: RNA), a biopharmaceutical company focused on developing Antibody Oligonucleotide Conjugates (AOCsā�), has announced its participation in three upcoming investor conferences in September 2025.
The management team will participate in fireside chats at the Cantor Global Healthcare Conference on September 3, the Wells Fargo Healthcare Conference on September 4, and the Morgan Stanley Global Healthcare Conference on September 8. Live webcasts and replays will be available on the company's investor relations website.
Avidity Biosciences (NASDAQ: RNA), azienda biofarmaceutica specializzata nello sviluppo di Antibody Oligonucleotide Conjugates (AOCsā�), ha comunicato la sua partecipazione a tre conferenze per investitori previste a settembre 2025.
Il team di management parteciperĆ a fireside chat al Cantor Global Healthcare Conference il 3 settembre, al Wells Fargo Healthcare Conference il 4 settembre e al Morgan Stanley Global Healthcare Conference l'8 settembre. Le webcast in diretta e le registrazioni saranno disponibili sul sito web per gli investitori della societĆ .
Avidity Biosciences (NASDAQ: RNA), compaƱĆa biofarmacĆ©utica enfocada en el desarrollo de Antibody Oligonucleotide Conjugates (AOCsā�), ha anunciado su participaciĆ³n en tres conferencias para inversores que se celebrarĆ”n en septiembre de 2025.
El equipo directivo participarĆ” en charlas tipo fireside en el Cantor Global Healthcare Conference el 3 de septiembre, en el Wells Fargo Healthcare Conference el 4 de septiembre y en el Morgan Stanley Global Healthcare Conference el 8 de septiembre. Las transmisiones en directo y las repeticiones estarĆ”n disponibles en la web de relaciones con inversores de la compaƱĆa.
Avidity Biosciences (NASDAQ: RNA)ė� ķģ²“-ģ¬ė¦¬ź³ ė“ķ“ė ģ¤ķģ“ė ź²°ķ©ģ²�(Antibody Oligonucleotide Conjugates, AOCsā�) ź°ė°ģ� ģ£¼ė „ķė ė°ģ“ģ¤ģ ģ½ģ¬ė”�, 2025ė � 9ģ� ź°ģµėė ģ� ź±“ģ ķ¬ģģ� ģ»Øķ¼ė°ģ¤ģ� ģ°øź°ķė¤ź³� ė°ķķģµėė¤.
ź²½ģģ§ģ 9ģ� 3ģ� Cantor Global Healthcare Conference, 9ģ� 4ģ� Wells Fargo Healthcare Conference, 9ģ� 8ģ� Morgan Stanley Global Healthcare Conferenceģģ ķģ“ģ“ģ¬ģ“ė ģ±ģ ģ°øģ¬ķ� ģģ ģ ėė�. ė¼ģ“ėø� ģ¹ģŗģ¤ķøģ ė¤ģė³“źø°ė� ķģ¬ģ� ķ¬ģģ� ź“ź³� ģ¹ģ¬ģ“ķøģģ ģ“ģ©ķ� ģ� ģģµėė¤.
Avidity Biosciences (NASDAQ: RNA), sociĆ©tĆ© biopharmaceutique spĆ©cialisĆ©e dans le dĆ©veloppement d'Antibody Oligonucleotide Conjugates (AOCsā�), a annoncĆ© sa participation Ć trois confĆ©rences investisseurs prĆ©vues en septembre 2025.
L'Ć©quipe de direction prendra part Ć des discussions informelles (fireside chats) lors du Cantor Global Healthcare Conference le 3 septembre, du Wells Fargo Healthcare Conference le 4 septembre et du Morgan Stanley Global Healthcare Conference le 8 septembre. Les webcasts en direct et les replays seront disponibles sur le site relations investisseurs de la sociĆ©tĆ©.
Avidity Biosciences (NASDAQ: RNA), ein biopharmazeutisches Unternehmen, das sich auf die Entwicklung von Antibody Oligonucleotide Conjugates (AOCsā�) spezialisiert hat, kĆ¼ndigte seine Teilnahme an drei bevorstehenden Investorenkonferenzen im September 2025 an.
Das Managementteam wird an Fireside-Chats beim Cantor Global Healthcare Conference am 3. September, beim Wells Fargo Healthcare Conference am 4. September und beim Morgan Stanley Global Healthcare Conference am 8. September teilnehmen. Live-Webcasts und Aufzeichnungen werden auf der Investor-Relations-Website des Unternehmens verfĆ¼gbar sein.
- None.
- None.
- Cantor Global Healthcare Conference 2025 ā�
New York, NY
Wednesday, September 3, 2025, at 7:20 a.m. PT | 10:20 a.m. ET - 2025 Wells Fargo Healthcare Conference ā�
Everett, MA
Thursday, September 4, 2025, at 9:45 a.m. PT | 12:45 p.m. ET - Morgan Stanley 23rd Annual Global Healthcare Conference ā�
New York, NY
Monday, September 8, 2025, at 10:50 a.m. PT | 1:50 p.m. ET
Live webcasts of each event, up-to-date event details and archived replays will be available on the "Events and Presentations" page in the "Investors" section of Avidity's website at .
About Avidity
Avidity Biosciences, Inc.'s mission is to profoundly improve people's lives by delivering a new class of RNA therapeutics - Antibody Oligonucleotide Conjugates (AOCsā�). Avidity is revolutionizing the field of RNA with its proprietary AOCs, which are designed to combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies to address targets and diseases previously unreachable with existing RNA therapies. Utilizing its proprietary AOC platform, Avidity demonstrated the first-ever successful targeted delivery of RNA into muscle and is leading the field with clinical development programs for three rare muscle diseases: myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD) and facioscapulohumeral muscular dystrophy (FSHD). Avidity is also advancing two wholly-owned precision cardiology development candidates addressing rare genetic cardiomyopathies. In addition, Avidity is broadening the reach of AOCs with its advancing and expanding pipeline including programs in cardiology and immunology through key partnerships. Avidity is headquartered in
Investor Contact:
Kat Lange
(619) 837-5014
[email protected]
View original content to download multimedia:
SOURCE Avidity Biosciences, Inc.
FAQ
When is Avidity Biosciences (RNA) presenting at the Cantor Global Healthcare Conference 2025?
What type of events will Avidity Biosciences (RNA) participate in at these healthcare conferences?
Where can investors watch Avidity Biosciences' (RNA) conference presentations?
What is Avidity Biosciences' (RNA) main focus as a company?
